Trillium Therapeutics Inc.

Trillium Therapeutics Inc. , based in Canada, specializes in developing innovative immuno-oncology therapies aimed at addressing significant unmet medical needs in cancer treatment. Founded in 2004 and headquartered in Mississauga, Canada, Trillium Therapeutics Inc. focuses on the development of therapies for cancer.

The company has engaged in three funding rounds, with the most recent being in February 2012, where it raised CAD 2 million from investors including Covington and GrowthWorks Capital, with prior participation from BDC Capital. Trillium Therapeutics Inc. is dedicated to advancing immuno-oncology treatments, working on innovative products designed to enhance patient outcomes in cancer care. The company's pipeline includes therapies that leverage the body’s immune system to fight cancer effectively.

Their services are directed towards healthcare providers and institutions involved in oncology, with the goal of providing cutting-edge solutions for cancer patients. Trillium Therapeutics Inc. generates revenue through the development and potential commercialization of its immuno-oncology therapies. The company’s revenue model is structured around partnerships and collaborations with healthcare providers, focusing on advancing its innovative treatments to meet specific medical needs in oncology.

In light of its recent fundraising round in February 2012, where Trillium Therapeutics Inc. secured CAD 2 million, the company plans to allocate these resources toward the development and clinical trials of its immuno-oncology products. The firm aims to expand its reach into new markets, with a focus on North America and Europe, to enhance the availability of its innovative therapies for cancer patients.